Related Experiment Videos
An epigenetically altered tumor cell vaccine.
A Nazmul H Khan1, William J Magner, Thomas B Tomasi
1Laboratory of Molecular Medicine, Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Cancer Immunology, Immunotherapy : CII
|March 5, 2004
Summary
Reversing gene silencing in tumor cells using a histone deacetylase inhibitor, trichostatin A (TSA), can enhance anti-tumor immunity. This epigenetic therapy approach shows promise for developing effective tumor vaccines.
Area of Science:
- Immunology
- Cancer Research
- Epigenetics
Background:
- Gene silencing through repression, a reversible process, can inactivate genes crucial for immunity.
- Chromatin modification offers a potential strategy to reverse gene silencing and restore immune function.
Purpose of the Study:
- To investigate if reversing gene silencing via chromatin acetylation can create an effective tumor vaccine.
- To explore the potential of epigenetic alterations in cancer cells for inducing tumor immunity.
Main Methods:
- Treatment of tumor cells in vitro with trichostatin A (TSA), a histone deacetylase inhibitor.
- Assessment of changes in immune gene expression (MHC class II, CD40, B7-1/2) post-TSA treatment.
- Evaluation of tumor growth delay, tumor-specific immunity, and T cell involvement in mouse models.
Main Results:
- TSA treatment altered the expression of key immune genes in tumor cells.
- TSA-treated tumor cells demonstrated delayed tumor growth in J558 plasmacytoma and B16 melanoma models.
- Approximately 30% of treated animals developed long-term tumor-specific immunity, with T cells playing a role.
Conclusions:
- Repression of immune genes contributes to tumor immune evasion.
- Epigenetically altered cancer cells represent a promising strategy for inducing tumor immunity.
- Further exploration of epigenetically modified cancer cells as a tumor vaccine approach is warranted.